Trial Profile
A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Erdafitinib (Primary) ; Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 30 Jan 2024 Planned End Date changed from 31 Dec 2023 to 25 Sep 2024.
- 21 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 24 May 2022 Planned primary completion date changed 31 Dec 2022.